|Bid||70.00 x 800|
|Ask||72.25 x 1300|
|Day's Range||70.37 - 71.50|
|52 Week Range||55.42 - 74.92|
|Beta (3Y Monthly)||1.51|
|PE Ratio (TTM)||142.37|
|Earnings Date||Jan 22, 2019 - Jan 28, 2019|
|Forward Dividend & Yield||1.12 (1.55%)|
|1y Target Est||79.44|
ABBOTT PARK, Ill., Dec. 14, 2018 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today increased the company's quarterly common dividend to 32 cents per share, marking a 14 percent increase. ...
Of the ten analysts covering DaVita (DVA), five have given it “buy” or higher ratings, four have given it “holds,” and one has given it a “sell.”
In the latest quarter, Abbott Laboratories’ (ABT) selling, general, and administrative expenses rose YoY (year-over-year) to $2.38 billion from $2.11 billion due to its Alere acquisition and expenditure for expanding the company’s different businesses. Meanwhile, its R&D (research and development) expenses rose YoY to $574.0 million from $568.0 million due to the Alere acquisition and increased cardiovascular and neuromodulation spending. It is expected to have R&D expenses of $2.25 billion and $2.36 billion, respectively, in fiscal 2018 and fiscal 2019, compared with $1. ...
Abbott Laboratories (ABT) offers products in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Cardiovascular and Neuromodulation Products. In this series, we’ll explore Abbott’s financials and valuation, and analysts’ views on its stock.
In fiscal 2018 and fiscal 2019, Abbott Laboratories (ABT) is expected to generate revenue of $30.66 billion and $32.21 billion, respectively, compared with revenue of $27.39 billion in fiscal 2017. Meanwhile, peers Biogen (BIIB), Johnson & Johnson (JNJ), and Pfizer (PFE) are expected to have revenue of $13.31 billion, $81.35 billion, and $53.59 billion, respectively, in fiscal 2018. Abbott’s cash per share is $4.20, while Biogen, Johnson & Johnson, and Pfizer have cash per share of $21.31, $7.20, and $2.90, respectively.
in connection with far-right extremism has risen by more than a third during the past year, new figures show. for far-right activity rose by 36 per cent in the year to March 2018, accounting for 18 per cent of all of those admitted to the programme, according to Home Office statistics. Referrals concerning individuals thought to be at risk of Islamist extremism fell by 14 per cent, but still make up the highest proportion of all programme admissions at 44 per cent.
The pharmaceutical sector delivers two benefits that appeal to investors: reasonable P/E ratios and growth catalysts. Many pharma stocks have suffered as of late. Some have key drugs facing patent expirations.
Medtronic (MDT) reported net income of $1.1 billion in the second quarter of fiscal 2019 compared to $2.0 billion in the second quarter of fiscal 2018. Medtronic’s net income in the first half of fiscal 2019 totaled $2.2 billion compared to $3.0 billion in the same period the prior year. Wall Street analysts anticipate that Medtronic is expected to report net income of $1.25 billion in the third quarter of fiscal 2019.
Medtronic (MDT) reported net revenues of $7.5 billion in the second quarter of fiscal 2019 compared to $7.1 billion in the second quarter of fiscal 2018, reflecting 6% YoY growth.
In November, Medtronic announced that the company would acquire Nutrino Health, a company that specializes in nutrition associated data services, analytics, and technologies. Medtronic’s diabetes segment is expected to improve significantly with the acquisition of Nutrino Health. The acquisition of Nutrino Health will bring together Nutrino Health’s robust food database, expertise in nutrition science and food analysis systems, and Medtronic’s innovative diabetes management resources.
Shire is a pharmaceutical company, with a wide range of products approved for use around the world. Some of the more familiar drugs the company produces include Adderall, prescribed for adult ADD, and Pentasa, used to treat Crohn's and other inflammatory bowel diseases. The company possesses both strength and weakness, and both are evident in the most recent quarterly report.
Why Has General Electric Stock Struggled in 2018? The Healthcare segment is the fourth-largest contributor to General Electric’s total revenues. As part of the company’s major restructuring plan in June, General Electric intends to spin off the segment and turn it into a standalone entity.
In December 2018, of the total 16 analysts covering Endo International (ENDP), five analysts have given Endo stock a “buy” or higher rating and 11 analysts have given it a “hold” rating. The mean rating for Endo International stock is 2.5 with a target price of $17.04, implying an upside potential of 47.3% over Endo International’s closing price of $11.57 on December 7, 2018.
ABBOTT PARK, Ill., Dec. 11, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the 37 th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 8, 2019 . Brian Yoor , executive vice president of ...
How's Endo International Positioned in December? Endo International (ENDP) incurred net interest expenses of $131.85 million in the third quarter of 2018 as compared with $127.52 million in the year-ago period. Endo International’s net loss per share was $0.43 in the third quarter of 2017.
Shares of generic drug makers fell sharply Monday, after a Washington Post report that an antitrust lawsuit brought by states over two drugs in 2016 has expanded into a major probe of alleged price-fixing across the industry.
Endo International’s (ENDP) next two business segments are: The US Generic Pharmaceuticals segment includes solid oral extended release, solid oral immediate release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, and sprays. Revenues from this segment declined from $294.75 million in the third quarter of 2017 to $257.97 million in the third quarter of 2018. The International Pharmaceuticals segment revenues also declined from $56.43 million in the third quarter of 2017 to $30.25 million in the third quarter of 2018.
Shares of generic drug makers fell sharply Monday, after a Washington Post report that an antitrust lawsuit brought by states over two drugs in 2016 has expanded into a major probe of alleged price-fixing. The case now involves at least 16 companies and 300 drugs, the report said, citing Joseph Nielsen, an assistant attorney general and antitrust investigator in Connecticut, who has been a leader in the probe. Nielsen is quoted as saying, "this is most likely the largest cartel in the history of the United States." The victims were consumers and taxpayers, who have been carrying the high cost of overcharges on common antiboitics, blood-pressure medications, arthritis treatments, anxiety pills and more, said the report. Teva Pharmaceuticals Industries Ltd. ADRs fell 5.7% on the news. Mylan NV was down 4.6%, and Dr. Reddy Labs Ltd was down 3%. Abbott Labs was down 1.4% and Pfizer Inc. was down 1.6%. The S&P 500 was down 1.8% and the Dow Jones Industrial Average was down about 2%.
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow over 700 of the best-performing investors and by analyzing their 13F filings, we can determine the stocks that they are collectively bullish […]
Jim Cramer flies through his responses to callers' stock questions, including one about the prospects for a drugmaker's stock.